Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Douglas A. McIntyre | Oct 23, 2007 at 6:55 AM EDT

Dendreon Sets Stage for 2008 for PROVENGE

Dendreon (NASDAQ:DNDN) has issued a press release noting that it has completed its target enrollment of 500 patients in phase…

Douglas A. McIntyre | Oct 21, 2007 at 10:17 AM EDT

For Boston Scientific And JNJ, The Stent Stats Get Worse

"William O’Neill, dean of clinical affairs at University of Miami’sMiller School of Medicine, says stent-patient traffic is beginning topick up…

Douglas A. McIntyre | Oct 18, 2007 at 5:09 PM EDT

Intuitive Surgical Earnings Stronger Than The Bionic Man (ISRG)

Intuitive Surgical Inc. (NASDAQ:ISRG) saw shares rise a monster 8.3% to $256.44 in active trading ahead of earnings. After the…

Douglas A. McIntyre | Oct 18, 2007 at 9:29 AM EDT

Nektar Crushed Under Pfizer’s Boot (NKTR, PFE)

Nektar Therapeutics (NASDAQ:NKTR) is seeing shares hitting 52-week lows after its pharmaceutical partner Pfizer Inc. (NYSE:PFE) unexpectedly said it would…

Douglas A. McIntyre | Oct 17, 2007 at 7:51 AM EDT

Medarex Hit With Sell Rating (MEDX, BMY)

Medarex (NASDAQ:MEDX) is seeing shares being hit by a research note where Banc of America initiated coverage with a "SELL"…

Douglas A. McIntyre | Oct 16, 2007 at 6:16 PM EDT

Cramer’s ‘Improving People’ Picks (ALGN, SNCI)

On tonight’s MAD MONEY on CNBC, Jim Cramer reviewed a couple stocks on what is basically a "bionic you." Obviously…

Douglas A. McIntyre | Oct 16, 2007 at 1:03 PM EDT

Boston Scientific (BSX) Tries To Fire Everyone

Will the last one to leave the building please turn out the lights? Boston Scientific (BSX) will apparently ax up…

Douglas A. McIntyre | Oct 16, 2007 at 9:07 AM EDT

Interpreting Amgen Sales From J&J’s PROCRIT (AMGN, JNJ)

Shares of Amgen Inc. (NASDAQ:AMGN) are under bit of pressure this morning, although not from any direct news from the…

Douglas A. McIntyre | Oct 15, 2007 at 3:18 PM EDT

Genentech’s Dribble (DNA)

Genentech (NYSE:DNA) posted $0.73 EPS vs $0.72 estimates, but revenues were $2.95 Billion versus a $2.93 Billion estimate. It looks…

Douglas A. McIntyre | Oct 15, 2007 at 11:26 AM EDT

Genentech To Set Biotech Sector Earnings Bias (DNA)

Genentech Inc. (NYSE:DNA) is set to report earnings after today’s close. First Call has consensus estimates at $0.72 EPS on…

Douglas A. McIntyre | Oct 15, 2007 at 7:34 AM EDT

Telik Surges on Trial Hold Release (TELK)

Telik, Inc. (NASDAQ:TELK) is seeing shares surging pre-market after it announced that the U.S. Food and Drug Administration has removed…

Douglas A. McIntyre | Oct 15, 2007 at 5:14 AM EDT

Pfizer’s Dump Internet Program

Pfizer (PFE) is hooking up with doctor social network Sermo. According to The Wall Street Journal: "Pfizer-affiliated doctors will be…

Douglas A. McIntyre | Oct 15, 2007 at 4:43 AM EDT

A Death Notice From Medtronic (MDT)

Medtronic (MDT) is warning doctors and patients to look at the company’s latest "defibrillator models because it was prone to…

Douglas A. McIntyre | Oct 13, 2007 at 8:40 AM EDT

Biogen Idec (BIIB) Puts Itself On The Block

Biotech firm Biogen Idec (BIIB) has put itself on the block, another victim of shareholder activist by Carl Icahn. The…

Douglas A. McIntyre | Oct 12, 2007 at 1:05 PM EDT

Evaluating Medarex & Bristol-Myers Huge Options Open Interest (MEDX, BMY, DNDN)

We were screening options activity today and something came up that where bets had significantly grown from our prior coverage. …

1 … 362 363 364 365 366 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Dendreon Sets Stage for 2008 for PROVENGE

For Boston Scientific And JNJ, The Stent Stats Get Worse

Intuitive Surgical Earnings Stronger Than The Bionic Man (ISRG)

Nektar Crushed Under Pfizer’s Boot (NKTR, PFE)

Medarex Hit With Sell Rating (MEDX, BMY)

Cramer’s ‘Improving People’ Picks (ALGN, SNCI)

Boston Scientific (BSX) Tries To Fire Everyone

Interpreting Amgen Sales From J&J’s PROCRIT (AMGN, JNJ)

Genentech’s Dribble (DNA)

Genentech To Set Biotech Sector Earnings Bias (DNA)

Telik Surges on Trial Hold Release (TELK)

Pfizer’s Dump Internet Program

A Death Notice From Medtronic (MDT)

Biogen Idec (BIIB) Puts Itself On The Block

Evaluating Medarex & Bristol-Myers Huge Options Open Interest (MEDX, BMY, DNDN)

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Health and Healthcare Articles

All Health and Healthcare Articles

Dendreon Sets Stage for 2008 for PROVENGE

For Boston Scientific And JNJ, The Stent Stats Get Worse

Intuitive Surgical Earnings Stronger Than The Bionic Man (ISRG)

Nektar Crushed Under Pfizer’s Boot (NKTR, PFE)

Medarex Hit With Sell Rating (MEDX, BMY)

Cramer’s ‘Improving People’ Picks (ALGN, SNCI)

Boston Scientific (BSX) Tries To Fire Everyone

Interpreting Amgen Sales From J&J’s PROCRIT (AMGN, JNJ)

Genentech’s Dribble (DNA)

Genentech To Set Biotech Sector Earnings Bias (DNA)

Telik Surges on Trial Hold Release (TELK)

Pfizer’s Dump Internet Program

A Death Notice From Medtronic (MDT)

Biogen Idec (BIIB) Puts Itself On The Block

Evaluating Medarex & Bristol-Myers Huge Options Open Interest (MEDX, BMY, DNDN)

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

Featured Reads

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%